Psilera Secures NIH Grant for Alcohol Use Disorder Research

Psilera Inc. has received a significant boost in its research efforts with a $2 million grant from the National Institutes of Health (NIH), announced in a press release. The grant, awarded by the National Institute on Alcohol Abuse and Alcoholism, will support Psilera's development of a novel neuroplastogen as a potential treatment for Alcohol Use Disorder (AUD).

The three-year, milestone-driven grant aims to advance Psilera's psilocybin derivative towards an Investigational New Drug (IND) application. This compound, selected from Psilera's Third Eye™ platform, targets the serotonin receptor 5-HT2A and has shown promise in pre-clinical studies as a non-opioid treatment for reducing alcohol consumption.

Psilera's research focuses on neuroplastogens, compounds that can reshape neuronal pathways in the brain, offering a potential new approach to treating AUD. If successful, this therapy could provide a non-hallucinogenic and non-addictive treatment alternative, potentially allowing for at-home administration and reducing the stigma associated with AUD treatment.